B.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
Arrowhead price target lowered to $38 from $51 at B. Riley
B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 ...
Arrowhead and Sarepta close $500 million licensing deal
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain ...
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns
Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations
First Quarter 2025 Results Key Financial Results Net loss: US$173.1m ...
Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports.
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.